Opioid analgesics elicit their effects via activation of the mu-opioid receptor (MOR), a G protein-coupled receptor known to interact with Ga i/o -type G proteins. Work in vitro has suggested that MOR couples preferentially to the abundant brain Ga i/o isoform, Ga o . However, studies in vivo evaluating morphine-mediated antinociception have not supported these findings. The aim of the present work was to evaluate the contribution of Ga o to MOR-dependent signaling by measuring both antinociceptive and biochemical endpoints in a Ga o null transgenic mouse strain. Male wild-type and Ga o heterozygous null (Ga o + /À) mice were tested for opioid antinociception in the hot plate test or the warm-water tail withdrawal test as measures of supraspinal or spinal antinociception, respectively. Reduction in Ga o levels attenuated the supraspinal antinociception produced by morphine, methadone, and nalbuphine, with the magnitude of suppression dependent on agonist efficacy. This was explained by a reduction in both high-affinity MOR expression and MOR agoniststimulated G protein activation in whole brain homogenates from Ga o + /À and Ga o homozygous null (Ga o À/À) mice, compared with wild-type littermates. On the other hand, morphine spinal antinociception was not different between Ga o + /À and wild-type mice and high-affinity MOR expression was unchanged in spinal cord tissue. However, the action of the partial agonist nalbuphine was compromised, showing that reduction in Ga o protein does decrease spinal antinociception, but suggesting a higher Ga o protein reserve. These results provide the first in vivo evidence that Ga o contributes to maximally efficient MOR signaling and antinociception.
INTRODUCTION
Opioid analgesics are prescribed for the management of moderate to severe pain. Clinically used opioids elicit their effects by stimulation of the mu-opioid receptor (MOR), a member of the G protein-coupled receptor superfamily that interacts with heterotrimeric G proteins (Gabg), which are defined in terms of the Ga subunit. Specifically, MOR couples to Ga proteins of the pertussis toxin-sensitive Ga i/o family, which comprises Ga o (including splice variants Ga o1 and Ga o2 ), Ga i1 , Ga i2 , and Ga i3 (Laugwitz et al, 1993; Chakrabarti et al, 1995) , as well as pertussis toxininsensitive Ga z (Garzon et al, 1997) . In the inactive state, Gabg exists in complex with the receptor. On agonist stimulation, GDP bound to the Ga subunit is exchanged for GTP, resulting in dissociation of active Ga-GTP from the Gbg heterodimer (reviewed in Brown and Sihra, 2008) ; both Ga-GTP and Gbg modulate effectors downstream of MOR, including adenylyl cyclase (AC) (Yu and Sadee, 1988) and calcium channels (Hescheler et al, 1987; Moises et al, 1994) . It has been shown that specific Ga i/o subunits differentially contribute to MOR-dependent behavioral responses, including morphine-mediated antinociception (Raffa et al, 1994; Sanchez-Blazquez et al, 2001) . However, findings are inconsistent because of the variety of methods and models utilized in previous work, such that the contribution of each Ga subunit to these responses is controversial.
Ga o is highly expressed in brain (Gierschik et al, 1986) . Multiple lines of evidence suggest that opioid agonists can activate MOR-G protein complexes in a non-selective manner, especially in heterologous expression systems (Laugwitz et al, 1993; Clark et al, 2006a; Clark and Traynor, 2006b ). On the other hand, the MOR-selective agonist ,N-MePhe 4 ,Gly-ol 5 ]enkephalin (DAMGO) was found to activate Ga o to a greater extent than either Ga i2 or Ga i3 (Clark et al, 2008) . Furthermore, in cultured neurons or neuronal-like cells, MOR has been shown to couple to AC (Carter and Medzihradsky, 1993) and N-type Ca 2 + channels (Hescheler et al, 1987; Moises et al, 1994) primarily via activation of Ga o . Despite the abundance of Ga o in the brain and evidence from in vitro studies that Ga o modulates signaling downstream of MOR, together with a recent report that Ga o may be involved in opioid dependence (Kest et al, 2009) , findings in vivo have primarily implicated Ga i2 and/or Ga z proteins as mediators of opioid agonist antinociception (Raffa et al, 1994; Sanchez-Blazquez et al, 1995 Standifer et al, 1996) . These studies utilized mice administered i.c.v. antisense oligodeoxynucleotides (ODNs) against a specific Ga subunit before antinociceptive testing of opioid agonists (i.c.v.) in the tail flick test (reviewed in Garzon et al, 2000) . However, there are a number of inherent difficulties with this technique, including proper verification of the extent of protein knockdown. For most of these studies, knockdown of Ga protein did not exceed B50% in peri-ventricular regions (eg, periaqueductal gray) (Sanchez-Blazquez et al, 1995) , while ODNs were less effective in brain regions more distal to the site of infusion (eg, thalamus), presumably due to poor diffusion (SanchezBlazquez et al, 1995; Standifer et al, 1996) . However, in one study, in which greater (B60-80%) knockdown of Ga subunits was achieved, ODNs directed against Ga o , in addition to other Ga isoforms, suppressed morphine antinociception (Standifer et al, 1996) . Clearly, inconsistencies in the efficacy and selectivity of Ga protein knockdown complicate the interpretation of these studies. This previous work is further limited in that only a single measure of opioid antinociception was evaluated.
This study was designed to test the hypothesis that MOR coupling to Ga o is necessary for opioid antinociception using a constitutive Ga o knockout mouse strain (Duan et al, 2007) . To probe the role of Ga o in MOR-mediated antinociception, opioid spinal and supraspinal antinociception were evaluated in response to noxious thermal stimuli; this is the first time that mice null for Ga o have been evaluated for alterations in MOR-dependent antinociception. Furthermore, to directly relate changes in opioid antinociception to alterations in MOR function, membrane homogenates from either whole brain or spinal cord of Ga o transgenic mice were evaluated for MOR expression and MOR agonist-stimulated G protein activity. These studies demonstrate that the abundant brain G protein, Ga o , is the primary Ga subtype responsible for MOR-mediated signaling and antinociception.
MATERIALS AND METHODS

Transgenic Mice
Transgenic mice null for Gnao1 (Ga o À/À), Gnai2 (Ga i2 À/À), or Gnai3 (Ga i3 À/À) were generated as previously described (Mortensen et al, 1992; Sowell et al, 1997; Duan et al, 2007) and were backcrossed onto the 129S6/SvEvTac strain for four generations. Transgenic mice and wild-type littermates were obtained by heterozygous breeding to control for genetic background. Adult, opioid-naïve male mice, matched for age, were utilized for all experiments. Mice were group-housed with food and water available ad libitum. Lights were maintained on a 12-h light-dark cycle (lights on at 0700 hours), and all testing was performed during the light phase. Studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the National Institutes of Health and all experimental protocols were approved by the University of Michigan Committee on the Use and Care of Animals.
Antinociceptive Tests
The hot plate test was used to evaluate supraspinal antinociception. Mice were given two injections of saline (i.p.) to determine baseline latency, followed by three cumulative doses of agonist (i.p.) in 15-min intervals (nalbuphine) or 30-min intervals (morphine and methadone). Where four doses of drug were used, dose-effect curves were generated by pooling data from two overlapping, cumulative dose-effect measurements. Mice were placed on a 52 or 55 1C hot plate at the appropriate interval following each injection and the latency to lick forepaw(s) or jump was measured with a cutoff time of 60 or 45 s for the 52 or 55 1C hot plate temperatures, respectively, in order to prevent tissue damage.
The warm-water tail withdrawal test was used to evaluate spinal antinociception. Mice were given a single injection of saline (i.p.) to determine baseline latency, followed by four cumulative doses of agonist (i.p.) in 15-min intervals (nalbuphine) or 30-min intervals (morphine). The distal tip of the mouse's tail was placed in a 50 or 55 1C warmwater bath at the appropriate interval following each injection and the latency to tail flick was measured with a cutoff time of 20 or 15 s for 50 or 55 1C water, respectively, in order to prevent tissue damage.
For both antinociceptive tests, agonist-stimulated antinociception is expressed as a percentage of maximum possible effect (% MPE), where % MPE ¼ (post-drug latencyÀbaseline latency) C (cutoff latencyÀbaseline latency) Â 100.
Membrane Preparation
Mice were euthanized by cervical dislocation. Whole brain tissue, minus cerebellum, or thoracic and lumbar spinal cord was removed, immediately chilled in ice-cold 50 mM Tris base, pH 7.4, and membrane homogenates were prepared as previously described (Lester and Traynor, 2006) . Final membrane pellets were resuspended in 50 mM Tris base, pH 7.4, aliquoted and stored at À80 1C. Protein content was determined using the method of Bradford (1976) .
Western Blot Analysis
Membranes from whole brain (20 mg protein) were mixed with sample buffer (63 mM Tris base, pH 6.8, 2% SDS, 10% glycerol, 0.008% bromophenol blue, and 50 mM dithiothreitol) and separated by SDS-PAGE on 10% (for detection of Ga o , Ga z , Ga i1 , Ga i2 , or Gb 1À4 ) or 15% polyacrylamide gels (for detection of Gg 2 ). Proteins were then transferred to nitrocellulose membranes (Pierce, Rockford, IL) and probed with either rabbit polyclonal anti-Ga o (1 : 1000; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-Ga z (1 : 200; Santa Cruz), rabbit polyclonal anti-Ga i1 (1 : 100; Santa Cruz), mouse monoclonal anti-Ga i2 (1 : 1000; Millipore, Billerica, MA), rabbit polyclonal antiGb 1À4 (1 : 500; Santa Cruz), or rabbit polyclonal anti-Gg 2 (1 : 200; Santa Cruz). Membranes from spinal cord (20 mg protein) were also evaluated for Ga o protein content, as above. All membranes were probed with mouse monoclonal anti-a-tubulin (1 : 1000; Sigma-Aldrich, St Louis, MO) as a loading control. Membranes were then incubated with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit secondary antibody (1 : 10 000; Santa Cruz). Antibody immunoreactivity was detected by enhanced chemiluminesence using an EpiChem3 Benchtop Darkroom (UVP, Upland, CA) and band densities were quantified using Image J software (http://rsbweb.nih.gov/ij/ index.html). Specifically, after background chemiluminesence was subtracted, G protein band densities were normalized to respective a-tubulin band densities and used to calculate expression relative to wild type for each G protein. 
Radioligand-Binding Assays
RESULTS
Characterization of Transgenic Mice Lacking Gao Protein
The full knockout, Ga o À/À mice did not often survive until weaning (B21 days), whereas wild-type and Ga o + /À mice were obtained at frequencies predicted by Mendeleian genetics (Table 1 ) (w 2 ¼ 11.07, df ¼ 1, po0.001). Peri-natal lethality was also noted in the initial reports of two independently generated Ga o null mouse strains (Valenzuela et al, 1997; Jiang et al, 1998) . These previous studies also reported several neurological abnormalities in Ga o À/À animals, including hyperactivity, tremor and turning behavior; however, no such gross behavioral abnormalities were noted for the Ga o + /À or Ga o À/À mice used in this study (Duan et al, 2007; unpublished observations 
Supraspinal Antinociception in Ga o Transgenic Mice
To determine whether Ga o is involved in opioid antinociception, Ga o + /À mice were evaluated for morphine antinociception in the hot plate test (Figure 1 ). In the 52 1C hot plate test, the baseline nociceptive threshold was not significantly different between wild-type (12.6 ± 0.6 s; n ¼ 30) and Ga o + /À mice (12.2 ± 0.5 s; n ¼ 32; t(60) ¼ 0.4885, p ¼ 0.627). Morphine produced a dosedependent increase in antinociception that was significantly reduced (B4-fold) in Ga o + /À mice when compared with wild-type controls, with ED 50 values of 47.7 mg/kg (31.2-72.9) and 11.4 mg/kg (5.9-22.1), respectively ( Figure 1a ). Although there was no significant interaction, there were significant main effects of dose and genotype (dose: F(2,36) ¼ 19.88; po0.001; genotype: F(1,36) ¼ 15.76, po0.001).
We hypothesized that increasing the efficacy requirements of the nociceptive system might further exaggerate this observed genotype difference; thus, the hot plate temperature was raised to 55 1C and Ga o transgenic mice were again evaluated for morphine supraspinal antinociception ( Figure 1b) . As expected, a decreased baseline nociceptive threshold was observed at the elevated hot plate temperature, and there were no significant differences between wild-type (7.5 ± 0.8 s; n ¼ 9) and Ga o + /À mice at baseline (6.6 ± 0.6 s; n ¼ 10;
Morphine dose-dependently produced antinociception in both wild-type and Ga o + /À mice, but the ED 50 was shifted B6-fold for Ga o + /À mice, with a value of 62.7 mg/kg (42.9-91.5) compared with 9.9 mg/kg (5.8-17.1) for wildtype littermates (Figure 1b ). There were significant main effects of both dose (F(2,51) ¼ 25.37; po0.001) and genotype (F(1,51) ¼ 41.98, po0.001), although there was no significant interaction. 
Asterisk indicates a statistical difference vs wild type by Bonferroni's post-test (po0.001). To determine whether Ga o has a role in the antinociception produced by opioid agonists other than morphine, Ga o transgenic mice were evaluated for either methadone or nalbuphine antinociception in the 52 1C hot plate test (Figures 1c and d) . Like morphine, methadone produced a dose-dependent increase in antinociception (Figure 1c ). The ED 50 value for wild-type mice was 13.0 mg/kg (10.1-16.8), which was B2-fold higher than the extrapolated ED 50 value for Ga o + /À mice of 5.8 mg/kg (4.4-7.6). There was no significant interaction; however, there were significant main effects of both dose (F(3,82) ¼ 33.12, po0.001) and genotype (F(1,82) ¼ 19.87, po0.001). The partial agonist nalbuphine also produced a dose-dependent stimulation of antinociception that was significantly reduced for Ga o + /À mice, compared with wild-type littermates (Figure 1d) 
Spinal Antinociception in Ga o Transgenic Mice
Ga o transgenic mice were also evaluated in the warm-water tail withdrawal test (Figure 2) , the same antinociceptive measure that was utilized in the majority of antisense ODN studies (Raffa et al, 1994; Sanchez-Blazquez et al, 1995 ). In the 50 1C tail withdrawal test, the baseline tail flick latency was not significantly different between wild-type (3.2±0.4 s; n ¼ 13) and Ga o + /À mice (4.2±0.6 s; n ¼ 15; t(26) ¼ 1.399, p ¼ 0.174). Morphine produced a dose-dependent increase in antinociception in both wild-type and Ga o + /À mice, with ED 50 values of 5.2 mg/kg (2.7-9.8) and 4.1 mg/kg (2.3-7.2), respectively ( Figure 2a ). There was a significant main effect of dose (F(3,44) ¼ 14.79, po0.001), although the main effect of genotype (F(1,44) ¼ 0.1024, p ¼ 0.751) and the dose Â genotype interaction were not significant.
Given that morphine behaves as a full agonist in this test, which may preclude the identification of small differences between genotypes, it was hypothesized that increasing the efficacy requirement of the system by raising the water bath temperature to 55 1C (Figure 2b) should allow for the identification of such differences. Again, as predicted, a decreased baseline nociceptive threshold was observed at the elevated water temperature, and there were also no significant differences between wild-type (1.9±0.1 s; n ¼ 8) and Ga o + /À mice in this test (1.8 ± 0.2 s; n ¼ 8; t(14) ¼ 0.6932, p ¼ 0.500). Against the 55 1C stimulus, morphine produced a dose-dependent increase in antinociception that was equivalent between wild-type and Ga o + /À mice, with ED 50 values of 8.2 mg/kg (5.5-12.5) and 7.4 mg/kg (5.5-10.0), respectively ( Figure 2b ). There was no significant interaction or significant effect of genotype (genotype: F(1,56) ¼ 0.2371, p ¼ 0.628), but there was a significant main effect of dose (dose: F(3,56) ¼ 124.0, po0.001).
As an alternative method of evaluating whether the efficacious antinociception produced by morphine was masking a mediatory role for Ga o , spinal antinociception was measured in the 50 1C warm-water tail withdrawal test in response to the low-efficacy agonist, nalbuphine (Figure 2c ). Nalbuphine produced a dose-dependent stimulation of spinal antinociception that was significantly reduced (B7-fold) in Ga o + /À mice when compared with wild-type littermates, with wild-type mice exhibiting an ED 50 value of 24.2 mg/kg (17.5-33.4) (Figure 2a ). Extrapolation of the nalbuphine dose-response for Ga o + /À mice revealed an ED 50 value of 176.1 mg/kg (113.3-273.8). 
Antinociception in Ga i2 and Ga i3 Transgenic Mice
To confirm the importance of Ga o for opioid antinociception, transgenic mice lacking either Ga i2 (Ga i2 heterozygous null, Ga i2 + /À; Ga i2 homozygous null, Ga i2 À/À) or Ga i3 (Ga i3 heterozygous null, Ga i3 + /À; Ga i3 homozygous null, Ga i3 À/À), together with their respective wild-type littermates, were evaluated in the 52 1C hot plate and 50 1C warm-water tail withdrawal tests (Figure 3 ). Both the Ga i2 and the Ga i3 transgenic mouse strains were generated in parallel with Ga o transgenic mice, and inactivation of the appropriate Ga subunit has been previously confirmed by western blot analysis (Sowell et al, 1997; Duan et al, 2007) . In the 52 1C hotplate test (Figures 3a and b) , the baseline response latency was equivalent among all Ga i2 transgenic mouse genotypes (wild-type: 12.0±0.7 s, n ¼ 10; Ga i2 + /À: 11.6 ± 0.7 s, n ¼ 9; Ga i2 À/À: 12.9 ± 0.7 s, n ¼ 8; F(2,24) ¼ 0.8112, p ¼ 0.456). Morphine produced a dose-dependent increase in antinociception that was not different between wild-type, Ga i2 + /À and Ga i2 À/À mice, with ED 50 values of 9.4 mg/kg (5.8-15.3), 12.0 mg/kg (6.9-20.8), and 10.6 mg/kg (6.0-18.8), respectively (Figure 3a) . There was a significant main effect of dose (F(2,72) ¼ 59.03, po0.001), but the main effect of genotype (F(2,72) ¼ 0.3274, p ¼ 0.722) and the dose Â genotype interaction were not significant. Similarly, in Ga i3 transgenic mice, morphine produced a dosedependent increase in antinociception that was equivalent between wild-type, Ga i3 + /À and Ga i3 À/À mice, with ED 50 values of 13.2 mg/kg (8.5-20.4), 10.6 mg/kg (6.0-18.9) and 8.1 mg/kg (4.4-15.0), respectively (Figure 3b ). There was a significant main effect of dose (F(2,69) ¼ 37.38, po0.001), but not genotype (F(2,69) ¼ 0.7686, p ¼ 0.468), and no significant interaction. There were also no genotypedependent differences observed in the baseline nociceptive threshold for these mice (wild-type: 13.3 ± 1.4 s, n ¼ 9; Ga i3 + /À: 16.8 ± 1.2 s, n ¼ 9; Ga i3 À/À: 16.2 ± 1.4 s, n ¼ 8;
Ga i2 and Ga i3 transgenic mice were also evaluated for spinal antinociception in the 50 1C tail withdrawal test (Figures 3c and d) . Baseline response latencies in this test were equivalent among all Ga i2 (wild-type: 5.0±0.4 s, n ¼ 9; Ga i2 + /À: 4.4 ± 0.6 s, n ¼ 8; Ga i2 À/À: 3.9 ± 0.5 s, n ¼ 6; Data represent the mean ± SEM for Ga i2 mice in the hot plate (n ¼ 8-10) and tail withdrawal tests (n ¼ 6-9) and for Ga i3 mice in the hot plate (n ¼ 8-9) and tail withdrawal tests (n ¼ 6-9). Legends for panels (c) and (d) are the same as for panels (a) and (b), respectively.
wild-type, Ga i2 + /À and Ga i2 À/À mice, with ED 50 values of 2.2 mg/kg (1.6-2.9), 2.0 mg/kg (1.6-2.6), and 2.2 mg/kg (1.5-3.3), respectively ( Figure 3c ). 
G Protein Expression in Ga o Transgenic Mouse Brain
Western blot analysis of G protein expression in whole brain membrane samples confirmed the loss of Ga o protein in Ga o À/À mice (Figure 4a ). Quantification of western blot images for Ga o revealed that, in comparison with wild-type controls, Ga o + /À mice express B60% less Ga o protein, which is close to the expected 50% reduction (Figure 4a) . 
MOR Expression in Ga o Transgenic Mouse Brain and Spinal Cord
To evaluate whether the reduction in opioid antinociception observed in Ga o + /À mice could be explained by alterations at the receptor level, MOR expression was measured in membranes from whole brain or from spinal cord of Ga o transgenic mice ( (Figure 5a ). There was a significant concentration Â genotype interaction for this response (F(14,39) DAMGO-stimulated binding was performed (Figure 5c ; Table 3 ) to measure the maximal number of G proteins (B max ) activated by agonist-occupied MOR and the ability of agonist to induce formation of GTP-bound Ga (KD) (Traynor and Nahorski, 1995; Selley et al, 1997) . In membranes from whole brain, DAMGO-stimulated [
35 S]GTPgS incorporation was increased as a function of increasing concentration of GTPgS, but was significantly reduced in Ga o + /À and Ga o À/À mice when compared with wild-type controls (Figure 5c ). There were significant main effects of both concentration and genotype, as well as a significant concentration Â genotype interaction (concentration: F(7,44) ¼ 37.50, po0.001; genotype: F(2,44) ¼ 79.22, po0.001; concentration Â genotype: F(14,44) ¼ 7.482, po0.001). This reduction was manifested as a decrease in B max for GTPgS binding (F(2,5) ¼ 9.359, p ¼ 0.020), without an accompanying change in the KD for GTPgS (Table 3) In spinal cord homogenates, basal levels of [ 35 S]GTPgS incorporation (Table 3) 
DISCUSSION
This study shows that reduction in the expression of the inhibitory Ga isoform, Ga o , attenuates MOR agonistmediated antinociception in mice at both the supraspinal and the spinal level. However, whether a genotypedependent difference was seen depended on the efficacy of the agonist and the strength of the noxious stimulus; a greater effect of the Ga o + /À genotype was manifested in the presence of the partial agonist nalbuphine or against a higher temperature stimulus. In contrast, there were no differences observed in the antinociceptive response to morphine in mice that were null for either Ga i2 or Ga i3 , compared with their respective wild-type littermates, at either the supraspinal or the spinal level. Furthermore, the loss of Ga o protein in Ga o À/À mice resulted in a decrease in Gb and Gg expression, a reduction in the number of high-affinity MOR-binding sites, and consequently, attenuation of MOR agonist-stimulated [ 
MOR Agonist-Mediated Antinociception
In wild-type mice, there was no difference in the potency of morphine observed at the higher hot plate temperature of 55 1C when compared with 52 1C, and morphine remained fully effective at both temperatures. However, this effect of temperature was exaggerated in Ga o + /À mice such that a larger shift in the potency of morphine was realized at the higher hot plate temperature, and even at 100 mg/kg, full antinociception was not attained. This suggests a reduced efficiency of antinociceptive processing in the Ga o + /À mice, leading to a higher agonist efficacy requirement. In confirmation of this, methadone, which has higher efficacy than morphine (Adams et al, 1990; Peckham and Traynor, 2006; McPherson et al, 2010) , showed a smaller genotype difference. These findings confirm a role for Ga o in opioid agonist-mediated supraspinal antinociception against a thermal stimulus, but also indicate that in the Ga o + /À mice, sufficient Ga o protein remains to give a robust response and/or that other Ga i/o proteins are involved in the response. However, this latter suggestion is less likely given the absence of a difference between Ga i2 or Ga i3 null mice and their wild-type littermates and the lack of compensatory changes in the expression of other Ga i/o proteins in Ga o null mice.
Surprisingly, in light of our findings using the hot plate test, but in agreement with previous ODN studies (Raffa et al, 1994; Sanchez-Blazquez et al, 1995 Standifer et al, 1996) , we did not observe a genotype-dependent difference in the ability of systemic morphine to produce antinociception between wild-type and Ga o + /À mice using the tail withdrawal test. However, we did see a profound shift in the potency of the partial agonist nalbuphine, which has lower efficacy than morphine (Dykstra et al, 1997; Selley et al, 1998) . This suggests, as with the hot plate test, that the relationship between the strength of the noxious stimulus and the efficacy of the ligand determines if a genotype difference is observed. These findings imply that blockade of spinal nociception, as measured in the tail withdrawal test, requires less agonist efficacy. As a result, even with a large reduction in Ga o protein, the system is still able to function efficiently.
Previous studies have shown that ODN knockdown of Ga subunits inhibits antinociception in an agonist-specific manner, suggesting that different agonists may cause MOR to signal through different Ga proteins. For example, antinociception induced by the partial agonist buprenorphine in the warm-water tail withdrawal test was significantly reduced after administration of antisense ODNs targeting Ga i2 , Ga i3 , Ga o2 , Ga z , or Ga q , whereas morphine antinociception was only attenuated in the presence of ODNs targeting Ga i2 or Ga z (Sanchez-Blazquez et al, 2001) . However, in our study, morphine antinociception in the tail withdrawal test was not altered on loss of Ga o , Ga i2 , or Ga i3 . Our findings indicate this may be due to differences in relative agonist efficacy, which suggests that there is a Ga o protein reserve for full agonists such that even a significant knockdown of Ga o does not necessarily alter the ability of morphine to elicit antinociception, whereas a partial agonist, such as nalbuphine, is more susceptible. Indeed, Standifer et al (1996) reported a reduction in morphine antinociception in the radiant-heat tail flick assay in mice exhibiting 460% knockdown of Ga o . On the other hand, the reason(s) why knockdown of Ga i2 and other Ga subunits affected antinociception in a ligand-dependent manner in previous studies is not clear, but may be due to differences in the route of administration (central vs peripheral) or the approach used (ODN vs constitutive knockdown). For example, in our constitutive knockdown, although no compensatory changes in Ga i/o protein expression were observed, other developmental changes may have occurred to substitute for the loss of Ga o specifically.
MOR-Dependent G Protein Activation
Loss of Ga o , as determined by western blot, was accompanied by a reduction in both Gb and Gg subunits. Valenzuela et al (1997) observed a similar decrease in Gb protein in ventricular membranes from a separately generated Ga o À/À mouse. This reduction in Gbg is likely due to the instability of these subunits in the absence of sufficient concentrations of Ga protein (Hwang et al, 2005) . A mechanism of regulated Ga and Gby expression would prevent the accumulation of free Gby dimers that are functionally competent in the absence of receptor agonist (Jiang et al, 1998) . Reductions in free Gb and Gg levels were not observed in brains from mice lacking either Ga i2 or Ga i3 (data not shown), presumably due to the lower expression levels of these Ga proteins.
This decrease in Ga o and accompanying Gb and Gg subunits, in addition to reducing the antinociceptive response, also reduced the ability of MOR agonists to stimulate [ (Jiang et al, 1998 (Jiang et al, , 2001 . The reduction in Ga o and cognate Gb and Gg subunits also resulted in a decrease in high-affinity MORbinding sites, but not total MOR sites, suggesting a reduction in heterotrimeric G protein coupling. However, high-affinity MOR binding was still present in the complete absence of Ga o , which could indicate that other Ga i/o subunits are taking the place of Ga o and providing a functional compensation, although there were no obvious increases in the levels of these isoforms. Indeed, analysis of DAMGO-stimulated [ 35 S]GTPgS saturation binding revealed a Ga protein to high-affinity MOR ratio (Ga : MOR) of approximately 34 : 1 in wild-type mice, compared with 24 : 1 in Ga o + /À mice and 10 : 1 in Ga o À/À mice. These results suggest that, in the brain, Ga proteins other than Ga o are able to form complexes with MOR. Such complexes might also help to translocate MOR to the cell surface, as with delta-opioid receptor (DOR)/Ga i2 complexes that are preassembled in secretory vesicles before delivery to the plasma membrane (Zhao et al, 2011) . However, G protein was not required for DOR translocation; if this was also true for MOR, it would explain the high level of low-affinity MOR present in the Ga o À/À mice.
In spinal cord homogenates, both total and high-affinity MOR numbers are considerably less than in whole brain of wild-type mice. Furthermore, there was no change in MOR expression observed in spinal cord tissue from Ga o + /À mice. This could be because of an overabundance of Ga o compared with MOR in the spinal cord. It is unlikely that other Ga subunits are making a bigger contribution in the spinal cord given that there is no difference in morphine antinociception in the tail withdrawal test between Ga i2 or Ga i3 null mice and their wild-type littermates. Similarly, differences between supraspinal and spinal antinociceptive circuitry have been demonstrated in a Ga z -deficient mouse (Hendry et al, 2000) , although the mechanisms underlying these supraspinal vs spinal differences were not further characterized. Together, these findings suggest that MOR signaling in the spinal cord may be more efficient, such that full behavioral responses can be achieved at much lower MOR expression and/or on activation of a smaller fraction of the total pool of G proteins.
Concluding Remarks
The present results using Ga o + /À mice demonstrate that Ga o has an important role in opioid antinociception. Moreover, changes observed in opioid antinociception in Ga o + /À mice were paralleled by similar alterations in opioid-dependent signaling at the cellular level. This conclusion is further supported by the recent work of Kest et al (2009) , who showed that Ga o expression modulates opioid dependence in mice by targeted knockdown of Ga o mRNA, which reduced the expression of withdrawal after chronic heroin or morphine. However, despite the strong evidence linking Ga o to opioid antinociception, these findings cannot be taken as absolute proof that MOR coupling to Ga o is required for morphine analgesia. Ga o is important for the signaling and activity of many neurotransmitter receptors in the central nervous system (reviewed in Jiang and Bajpayee, 2009 ). Thus, it is possible that non-opioid pathways are compromised in the Ga o + /À mice and contribute to the altered antinociceptive responses (Connor and Christie, 1999) . These and other questions related to the consequences of regional knockdown of Ga o will be addressed in future studies. Nevertheless, the finding that in addition to antinociception, both high-affinity MOR expression and MOR agonist-stimulated G protein activity are reduced strongly supports the notion that the Ga o -MOR complex has a key role in opioid antinociception.
